Press releases

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Canaccord Genuity 9th Annual Medical Technology and Diagnostics Forum on November 19, in New York City. David Pierce,...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Stifel Healthcare Conference on November 17, in New York City. Susie Lisa, vice president, Investor Relations, will...

Boston Scientific Corporation (NYSE: BSX) generated sales of $1.888 billion during the third quarter ended September 30, 2015, compared to the company's guidance range for the quarter of $1.790 to...

Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve...

Boston Scientific (NYSE: BSX) this week announced the start of the Boston Scientific Connected Patient Challenge, an open innovation contest designed to encourage advancements in the use of remote...

Boston Scientific (NYSE: BSX) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral interventions portfolios to be shared at the 27th...

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2015 on Wednesday, October...

Boston Scientific Corporation (NYSE: BSX) announced today the launch of the Captivator™ EMR Device for Endoscopic Mucosal Resection (EMR), a minimally invasive alternative to an esophagectomy, a...

New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...